Charles Chesnelong

Charles Chesnelong is a Field Application Scientist within Cytiva’s Nanomedicine team, supporting the pharmaceutical development of lipid nanoparticle (LNP) therapeutics. His scientific interests focus on the development and application of LNPs across a range of therapeutic modalities, including in vivo CAR-T, gene replacement, gene editing, gene silencing, and vaccines for infectious diseases and cancer immunotherapy.